Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Yuqin Song, Qingqing Cai, Keshu Zhou, Ming Jiang, Zhengming Jin, Lei Zhang, Xiuhua Sun, Haiyan Yang, Lanfang Li, Kaiyang Ding, Junyuan Qi, Hongmei Jing, Wei Yang, Min Zhou, Jun Ma, Zhigang Peng, Wei Xu, Hui Zhou, Li Yu, Yuankai Shi, Guohui Cui, Zheng Wang, Nawei Liu, Yejiang Lou, Yue Shen, Yi Chen, Fenlai Tan, Jun Zhu
Institutions: Peking University Cancer Hospital, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Zhengzhou University, Henan Cancer Hospital, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, First Affiliated Hospital of Soochow University, First Affiliated Hospital of Zhengzhou University, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, University of Science and Technology of China, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Peking University Third Hospital, Sheng Jing Hospital, China Medical University, Guangzhou Medical University Cancer Hospital, Guangzhou Medical University, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University, Jiangsu Province Hospital, Central South University, Hunan Cancer Hospital, Second Affiliated Hospital of Nanchang University, Wuhan Union Hospital, Huazhong University of Science and Technology, Presage Biosciences (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405039141